PF-06882961 Chemical Properties

Boiling point:

782.6±60.0 °C(Predicted)

Density 

1.39±0.1 g/cm3(Predicted)

storage temp. 

Store at -20°C

solubility 

DMSO:10.0(Max Conc. mg/mL);18.0(Max Conc. mM)
Ethanol:100.0(Max Conc. mg/mL);179.98(Max Conc. mM)

form 

Solid powder

pka

3.41±0.30(Predicted)

InChIKey

HYBAKUMPISVZQP-DEOSSOPVSA-N

SMILES

C1(CN2CCC(C3=NC(OCC4=CC=C(C#N)C=C4F)=CC=C3)CC2)N(C[C@@H]2CCO2)C2=CC(C(O)=O)=CC=C2N=1

PF-06882961 Usage And Synthesis

Uses

PF-06882961 is a potent, orally bioavailable glucagon-like peptide-1 receptor agonist (GLP-1R) agonist. It has blood glucose lowering and weight loss properties and is used to treat type 2 diabetes (T2D) and obesity.

in vitro

For example, a methylene-linked oxetane increased potency ~100-fold relative to the methyl substituent of 5, leading to the identification of PF-06882961, which is a full agonist (EC50 = 13 nM) in the CS cAMP assay. PF-06882961 also incorporates a nitrile replacement for the chloride in the benzyl ether region, which served to reduce CLint in HLM as well as in human hepatocytes.
Reference: J Med Chem. 2022 Jun 23;65(12):8208-8226. https://pubmed.ncbi.nlm.nih.gov/35647711/

in vivo

Intravenous infusion of PF-06882961 during the IVGTT led to an increase in insulin secretion and the rate of glucose disappearance (K-value). Enhancement of glucose-stimulated insulin secretion by PF-06882961 was concentration-dependent and was also observed following oral dosing with similar efficacy when compared to administration by IV infusion. Once-daily administration of PF-06882961 for 2 days also inhibited food intake compared to vehicle-treated monkeys.
Reference: J Med Chem. 2022 Jun 23;65(12):8208-8226. https://pubmed.ncbi.nlm.nih.gov/35647711/

target

PF-06882961, a non-peptide agonist, activates the canonical G protein signaling activity only in the Glucagon-like peptide-1 (GLP-1) receptor with Trp33ECD.

PF-06882961(2230198-02-2)Related Product Information

• PF04191834
• N-Methyl-N-[2-[[[2-[(2-oxo-2,3-dihydro-1H-indol-5-yl)amino]-5-trifluoromethylpyrimidin-4-yl]amino]methyl]phenyl]methanesulfonamide
• PF 573228
• 6-chloro-5-(4-(1-hydroxycyclobutyl)phenyl)-1H-indole-3-carboxylicacid
• 6-chloro-5-(4-(1-hydroxycyclobutyl)phenyl)-1H-indole-3-carboxylicacid
• PF-04979064
• PF-3758309
• PF-05212384
• PF-06281355
• PF-562271
• Ketohexokinase inhibitor 1
• PF-6274484
• PF-9366
• 4-[(Diethylamino)methyl]-N-[2-(2-methoxyphenyl)ethyl]-N-(3R)-3-pyrrolidinylbenzamide
• 3-(5-fluoro-indol-3-yl)-pyrrolidine-2,5-dione
• PF06869206
• PF-06372222
• PF-232798